Ruediger C Braun-Dullaeus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9042851/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ethnic comparison in takotsubo syndrome: novel insights from the International Takotsubo Registry. Clinical Research in Cardiology, 2022, 111, 186-196.	3.3	8
2	Cigarette Smoke Extract Disturbs Mitochondria-Regulated Airway Epithelial Cell Responses to Pneumococci. Cells, 2022, 11, 1771.	4.1	3
3	Pressure–volume loop validation of TAPSE/PASP for right ventricular arterial coupling in heart failure with pulmonary hypertension. European Heart Journal Cardiovascular Imaging, 2021, 22, 168-176.	1.2	40
4	Prognostic impact of acute pulmonary triggers in patients with takotsubo syndrome: new insights from the International Takotsubo Registry. ESC Heart Failure, 2021, 8, 1924-1932.	3.1	8
5	Predictors and prognosis of right ventricular function in pulmonary hypertension due to heart failure with reduced ejection fraction. ESC Heart Failure, 2021, 8, 2968-2981.	3.1	23
6	Predictive Value of Plasma NGAL:Hepcidin-25 for Major Adverse Kidney Events After Cardiac Surgery with Cardiopulmonary Bypass: A Pilot Study. Annals of Laboratory Medicine, 2021, 41, 357-365.	2.5	6
7	Impact of Atrial Fibrillation on Outcome in Takotsubo Syndrome: Data From the International Takotsubo Registry. Journal of the American Heart Association, 2021, 10, e014059.	3.7	18
8	Biomarker-Guided Risk Assessment for Acute Kidney Injury: Time for Clinical Implementation?. Annals of Laboratory Medicine, 2021, 41, 1-15.	2.5	46
9	Healthcare professionals' perceptions of impacts of the Covid-19-pandemic on outpatient care in rural areas: a qualitative study. BMC Health Services Research, 2021, 21, 1298.	2.2	16
10	Clinical correlates and prognostic impact of neurologic disorders in Takotsubo syndrome. Scientific Reports, 2021, 11, 23555.	3.3	13
11	Urinary Biomarkers may Complement the Cleveland Score for Prediction of Adverse Kidney Events After Cardiac Surgery: A Pilot Study. Annals of Laboratory Medicine, 2020, 40, 131-141.	2.5	25
12	Impact of aspirin on takotsubo syndrome: a propensity scoreâ€based analysis of the InterTAK Registry. European Journal of Heart Failure, 2020, 22, 330-337.	7.1	24
13	Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 279-287.	2.4	34
14	Coexistence and outcome of coronary artery disease in Takotsubo syndrome. European Heart Journal, 2020, 41, 3255-3268.	2.2	49
15	DNA-PK: gatekeeper for IKKγ/NEMO nucleocytoplasmic shuttling in genotoxic stress-induced NF-kappaB activation. Cellular and Molecular Life Sciences, 2020, 77, 4133-4142.	5.4	14
16	Age-Related Variations in Takotsubo Syndrome. Journal of the American College of Cardiology, 2020, 75, 1869-1877.	2.8	42
17	Clinical Features and Outcomes of Patients With Malignancy and Takotsubo Syndrome: Observations From the International Takotsubo Registry. Journal of the American Heart Association, 2019, 8, e010881.	3.7	63
18	Clinical Predictors and Prognostic Impact of Recovery of Wall Motion Abnormalities in Takotsubo Syndrome: Results From the International Takotsubo Registry. Journal of the American Heart Association, 2019, 8, e011194.	3.7	27

#	Article	IF	CITATIONS
19	Outcomes Associated With Cardiogenic Shock in Takotsubo Syndrome. Circulation, 2019, 139, 413-415.	1.6	75
20	Prediction of short―and longâ€ŧerm mortality in takotsubo syndrome: the InterTAK Prognostic Score. European Journal of Heart Failure, 2019, 21, 1469-1472.	7.1	20
21	A Secreted Phospholipase A2 Induces Formation of Smooth Muscle Foam Cells Which Transdifferentiate to Macrophage-Like State. Molecules, 2019, 24, 3244.	3.8	18
22	Cardiac arrest in takotsubo syndrome: results from the InterTAK Registry. European Heart Journal, 2019, 40, 2142-2151.	2.2	79
23	Right heart function interacts with left ventricular remodeling after CRT: A pressure volume loop study. International Journal of Cardiology, 2018, 268, 156-161.	1.7	11
24	Impact of internal and external electrical cardioversion on cardiac specific enzymes and inflammation in patients with atrial fibrillation and heart failure. Journal of Cardiology, 2018, 72, 135-139.	1.9	4
25	JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation. Journal of Clinical Investigation, 2018, 128, 4359-4371.	8.2	88
26	Long-Term Prognosis of Patients With Takotsubo Syndrome. Journal of the American College of Cardiology, 2018, 72, 874-882.	2.8	224
27	Semiautomatic High-Content Analysis of Complex Images from Cocultures of Vascular Smooth Muscle Cells and Macrophages: A CellProfiler Showcase. SLAS Discovery, 2017, 22, 837-847.	2.7	2
28	Systemic application of sirolimus prevents neointima formation not via a direct anti-proliferative effect but via its anti-inflammatory properties. International Journal of Cardiology, 2017, 238, 79-91.	1.7	15
29	RSK-mediated nuclear accumulation of the cold-shock Y-box protein-1 controls proliferation of T cells and T-ALL blasts. Cell Death and Differentiation, 2017, 24, 371-383.	11.2	15
30	Targeting of Extracellular RNA Reduces Edema Formation and Infarct Size and Improves Survival After Myocardial Infarction in Mice. Journal of the American Heart Association, 2017, 6, .	3.7	27
31	Intravital Microscopy of Monocyte Homing and Tumor-Related Angiogenesis in a Murine Model of Peripheral Arterial Disease. Journal of Visualized Experiments, 2017, , .	0.3	2
32	Factor VII activating protease (FSAP) influences vascular remodeling in the mouse hind limb ischemia model. American Journal of Translational Research (discontinued), 2017, 9, 3084-3095.	0.0	7
33	Takotsubo Cardiomyopathy: What we have Learned in the Last 25 Years? (A Comparative Literature) Tj ETQq1	1 0.784314 1.5	rg_{13}^{BT} /Overla
34	GSK-3β controls NF-kappaB activity via IKKγ/NEMO. Scientific Reports, 2016, 6, 38553.	3.3	73
35	Happy heart syndrome: role of positive emotional stress in takotsubo syndrome. European Heart Journal, 2016, 37, 2823-2829.	2.2	136
36	A 2-Step Extra-Anatomic Bypass Rescue Procedure for Bridging Aortic Coarctation in a Patient With Multiorgan Failure. Circulation, 2016, 133, 914-915.	1.6	0

#	Article	IF	CITATIONS
37	Relationships of peripheral IGF-1, VEGF and BDNF levels to exercise-related changes in memory, hippocampal perfusion and volumes in older adults. NeuroImage, 2016, 131, 142-154.	4.2	236
38	Effects of the Peroxisome Proliferator-Activated Receptor-Î ³ Agonist Pioglitazone on Peripheral Vessel Function and Clinical Parameters in Nondiabetic Patients: A Double-Center, Randomized Controlled Pilot Trial. Cardiology, 2015, 131, 165-171.	1.4	3
39	DNA-dependent protein kinase (DNA-PK) permits vascular smooth muscle cell proliferation through phosphorylation of the orphan nuclear receptor NOR1. Cardiovascular Research, 2015, 106, 488-497.	3.8	25
40	Effects of dronedarone on ventricular repolarization and repolarization dynamics in patients with preserved left ventricular systolic function. International Journal of Cardiology, 2015, 185, 119-121.	1.7	0
41	Feasibility of a new method using two-dimensional transesophageal echocardiography for aortic annular sizing in patients undergoing transcatheter aortic valve implantation; a case–control study. BMC Cardiovascular Disorders, 2015, 15, 78.	1.7	0
42	Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. New England Journal of Medicine, 2015, 373, 929-938.	27.0	1,827
43	Effects of the PPARÎ ³ agonist pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non-diabetic patients: a double-center, randomized controlled VH-IVUS pilot-trial. Heart and Vessels, 2015, 30, 286-295.	1.2	11
44	Marked Prolongation of QRS Duration after Initiation of Dronedarone Therapy. Heart International, 2014, 9, HEART.2014.1249.	1.4	1
45	Tetanus Toxoidâ€Pulsed Monocyte Vaccination for Augmentation of Collateral Vessel Growth. Journal of the American Heart Association, 2014, 3, e000611.	3.7	4
46	CD4+ T Cells from Human Neonates and Infants Are Poised Spontaneously To Run a Nonclassical IL-4 Program. Journal of Immunology, 2014, 192, 5160-5170.	0.8	64
47	Marked prolongation of QRS duration after initiation of dronedarone therapy. Heart International, 2014, 9, 33-5.	1.4	1
48	Uncoupled eNOS annihilates neuregulin-1β-induced cardioprotection: a novel mechanism in pharmacological postconditioning in myocardial infarction. Molecular and Cellular Biochemistry, 2013, 373, 115-123.	3.1	9
49	Ephrin-A1/EphA4-mediated adhesion of monocytes to endothelial cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 2201-2211.	4.1	42
50	Exercise intolerance in patients on dronedarone. What is the underlying mechanism?. International Journal of Cardiology, 2013, 168, 4824-4825.	1.7	1
51	Efficacy and safety profile of dronedarone in clinical practice. Results of the Magdeburg Dronedarone Registry (MADRE study). International Journal of Cardiology, 2013, 167, 2600-2604.	1.7	14
52	Influence of oral antiplatelet therapy on hemorrhagic complications of pacemaker implantation. Clinical Research in Cardiology, 2013, 102, 345-349.	3.3	10
53	Unusual aortic perforation after transcutaneous aortic valve implantation. European Heart Journal, 2013, 34, 1049-1049.	2.2	1
54	The lysosomal transfer of LDL/cholesterol from macrophages into vascular smooth muscle cells induces their phenotypic alteration. Cardiovascular Research, 2013, 97, 544-552.	3.8	30

#	Article	IF	CITATIONS
55	Which Patient is Most Likely to Benefit From Dronedarone? Analysis From the Magdeburg Dronedarone Registry (MADRE Study). Journal of Clinical Pharmacology, 2013, 53, 841-845.	2.0	1
56	Role of the Phosphatase PTEN in Early Vascular Remodeling. PLoS ONE, 2013, 8, e55445.	2.5	20
57	Transplantation of bone marrow derived monocytes: a novel approach for augmentation of arteriogenesis in a murine model of femoral artery ligation. American Journal of Translational Research (discontinued), 2013, 5, 155-69.	0.0	10
58	The dissimilar siblings or: the NFAT-modulated yin and yang of AIF-1 and IRT-1 in cardiovascular diseases. Cardiovascular Research, 2012, 93, 388-389.	3.8	1
59	Treatment with aliskiren/amlodipine combination in patients with moderate-to-severe hypertension: a randomised, double-blind, active comparator trial. International Journal of Clinical Practice, 2012, 66, 834-842.	1.7	5
60	Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: Design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. American Heart Journal, 2012, 163, 938-945.	2.7	135
61	Efficacy and safety profile of dronedarone in clinical practice. Preliminary results of the Magdeburg Dronedarone Registry. International Journal of Cardiology, 2012, 157, 303-304.	1.7	10
62	Decreased meropenem levels in Intensive Care Unit patients with augmented renal clearance: benefit of therapeutic drug monitoring. International Journal of Antimicrobial Agents, 2012, 40, 370-372.	2.5	62
63	Intra-Atrial Endothelial Lesion Resulting from Transseptal Puncture for Catheter Ablation of Atrial Fibrillation. Heart International, 2012, 7, hi.2012.e8.	1.4	0
64	A Natural-History Study of Coronary Disease. New England Journal of Medicine, 2011, 364, 1469-1472.	27.0	3
65	Infections due to Pseudallescheria/Scedosporium species in patients with advanced HIV disease — a diagnostic and therapeutic challenge. International Journal of Infectious Diseases, 2011, 15, e422-e429.	3.3	29
66	Comment on the European guidelines for the management of atrial fibrillation. Clinical Research in Cardiology, 2011, 100, 543-544.	3.3	4
67	OxLDL and macrophage survival: essential and oxygen-independent involvement of the Hif-pathway. Basic Research in Cardiology, 2011, 106, 761-772.	5.9	28
68	Cell-specific and hypoxia-dependent regulation of human HIF-3α: inhibition of the expression of HIF target genes in vascular cells. Cellular and Molecular Life Sciences, 2011, 68, 2627-2642.	5.4	51
69	Ceneration of Mature Murine Monocytes from Heterogeneous Bone Marrow and Description of Their Properties. Journal of Histochemistry and Cytochemistry, 2011, 59, 813-825.	2.5	101
70	Ultrasound guided thrombin injection of pseudoaneurysm of the radial artery after percutaneous coronary intervention. Vasa - European Journal of Vascular Medicine, 2011, 40, 78-81.	1.4	14
71	Inhibition of Matrix Deposition: A New Strategy for Prevention of Restenosis After Balloon Angioplasty. Journal of Cardiovascular Pharmacology, 2010, 55, 213-218.	1.9	6
72	Transcriptional regulation of Pim-1 kinase in vascular smooth muscle cells and its role for proliferation. Basic Research in Cardiology, 2010, 105, 267-277.	5.9	47

#	Article	IF	CITATIONS
73	Transcriptional activation of DNAâ€dependent protein kinase catalytic subunit gene expression by oestrogen receptorâ€Î±. EMBO Reports, 2010, 11, 208-213.	4.5	22
74	Interaction of the Double-Strand Break Repair Kinase DNA-PK and Estrogen Receptor-α. Molecular Biology of the Cell, 2010, 21, 1620-1628.	2.1	52
75	Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: Design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial. American Heart Journal, 2010. 159. 547-554.	2.7	64
76	Impact of Dendritic Cells on Vascular Biology. Current Hypertension Reviews, 2009, 5, 49-53.	0.9	1
77	Platelet interactions as therapeutic targets for prevention of atherothrombosis. Future Cardiology, 2009, 5, 285-296.	1.2	3
78	The nucleotide analogue 3-deazaadenosine prevents neointima-formation after balloon injury. Biochemical and Biophysical Research Communications, 2009, 378, 826-831.	2.1	0
79	Deazaadenosine Prevents Leukozyte Evasion During Acute Cardiac Allograft Rejection by Suppression of Adhesion Molecule Expression. Transplantation Proceedings, 2009, 41, 2628-2630.	0.6	1
80	Serial Assessment of Ventricular Morphology and Function. Heart Failure Clinics, 2009, 5, 301-314.	2.1	8
81	Chelerythrine treatment influences the balance of pro- and anti-apoptotic signaling pathways in the remote myocardium after infarction. Molecular and Cellular Biochemistry, 2008, 310, 119-128.	3.1	13
82	Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?. Clinical Research in Cardiology, 2008, 97, 797-800.	3.3	9
83	Indocyanine green angiography: A new method to quantify collateral flow in mice. Journal of Vascular Surgery, 2008, 48, 1315-1321.	1.1	21
84	Chronic NOS inhibition prevents adverse lung remodeling and pulmonary arterial hypertension in caveolin-1 knockout mice. Pulmonary Pharmacology and Therapeutics, 2008, 21, 507-515.	2.6	60
85	The adverse cardiopulmonary phenotype of caveolin-1 deficient mice is mediated by a dysfunctional endothelium. Journal of Molecular and Cellular Cardiology, 2008, 44, 938-947.	1.9	54
86	Nitric oxide synthases are crucially involved in the development of the severe cardiomyopathy of caveolin-1 knockout mice. Biochemical and Biophysical Research Communications, 2008, 377, 769-774.	2.1	17
87	Fatty acids differentially influence phosphatidylinositol 3-kinase signal transduction in endothelial cells: Impact on adhesion and apoptosis. Atherosclerosis, 2008, 197, 630-637.	0.8	24
88	Atrial fibrillation is associated with impaired cognitive function and hippocampal atrophy: silent cerebral ischaemia vs. Alzheimer's disease?. European Heart Journal, 2008, 29, 2067-2069.	2.2	7
89	Calpain counteracts mechanosensitive apoptosis of vascular smooth muscle cells <i>in vitro</i> and <i>in vivo</i> . FASEB Journal, 2008, 22, 579-589.	0.5	18
90	Regulation of hypoxia-inducible factors in human macrophages—involvement of the natural antisense of Hif-1α (AIHF). Journal of Molecular and Cellular Cardiology, 2007, 42, S75-S76.	1.9	0

#	Article	IF	CITATIONS
91	Role of the Pim-1 kinase for vasculoproliferative processes in the context of the atherosclerotic plaque milieu. Journal of Molecular and Cellular Cardiology, 2007, 42, S223.	1.9	0
92	Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice. Respiratory Research, 2007, 8, 15.	3.6	87
93	Neurokinin†receptor activation induces reactive oxygen species and epithelial damage in allergic airway inflammation. Clinical and Experimental Allergy, 2007, 37, 1788-1797.	2.9	28
94	Disruption of caveolin-1 leads to enhanced nitrosative stress and severe systolic and diastolic heart failure. Biochemical and Biophysical Research Communications, 2006, 340, 702-708.	2.1	63
95	Different expression pattern of hypoxia-inducible factor-1α (Hif-1α) and hypoxia-inducible factor-2α (Hif-2α) in human monocytes and monocyte-derived macrophages. Journal of Molecular and Cellular Cardiology, 2006, 40, 1005.	1.9	0
96	Isolation and transduction of monocytes: promising vehicles for therapeutic arteriogenesis. Langenbeck's Archives of Surgery, 2006, 391, 72-82.	1.9	12
97	Caveolin-1: Dual Role for Proliferation of Vascular Smooth Muscle Cells. Trends in Cardiovascular Medicine, 2006, 16, 50-55.	4.9	38
98	Caveolae and caveolin in transmembrane signaling: Implications for human disease. Cardiovascular Research, 2006, 70, 42-49.	3.8	86
99	Apoptosis of human macrophages by Flt-4 signaling: Implications for atherosclerotic plaque pathology. Cardiovascular Research, 2006, 71, 774-784.	3.8	29
100	The G534E polymorphism of the gene encoding the factor VII–activating protease is associated with cardiovascular risk due to increased neointima formation. Journal of Experimental Medicine, 2006, 203, 2801-2807.	8.5	71
101	Transregulation of the α2-Adrenergic Signal Transduction Pathway by Chronic β-Blockade. Journal of Cardiovascular Pharmacology, 2005, 45, 253-259.	1.9	8
102	Comparative morphometric and immunohistological assessment of the development of restenosis after arterial injury and a cholesterol-rich diet in apolipoprotein E ???/???mice and C57BL/6 control mice. Coronary Artery Disease, 2005, 16, 391-400.	0.7	5
103	Near syncope while chewing food. Clinical Research in Cardiology, 2005, 94, 740-741.	1.1	0
104	Decreased caveolin-1 in atheroma: Loss of antiproliferative control of vascular smooth muscle cells in atherosclerosis. Cardiovascular Research, 2005, 68, 128-135.	3.8	40
105	Caveolin-1 Facilitates Mechanosensitive Protein Kinase B (Akt) Signaling In Vitro and In Vivo. Circulation Research, 2005, 96, 635-642.	4.5	152
106	The expression of macrophage migration inhibitory factor 1α (MIF 1α) in human atherosclerotic plaques is induced by different proatherogenic stimuli and associated with plaque instability. Atherosclerosis, 2005, 178, 83-94.	0.8	65
107	In Vitro Cultivation of Vascular Smooth Muscle Cells. , 2005, , 630-639.		2
108	Cell Cycle–Dependent Regulation of Smooth Muscle Cell Activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 845-850.	2.4	65

#	Article	IF	CITATIONS
109	Transplantation of Monocytes: A Novel Strategy forIn VivoAugmentation of Collateral Vessel Growth. Human Gene Therapy, 2004, 15, 1-12.	2.7	54
110	3-Deazaadenosine prevents leukocyte invasion by suppression of adhesion molecule expression during acute cardiac allograft rejection: Involvement of apoptotic cell death. Journal of Heart and Lung Transplantation, 2004, 23, 970-978.	0.6	9
111	Quantification of the cell-cycle inhibitors p27Kip1 and p21Cip1 in human atherectomy specimens: Primary stenosis versus restenosis. Translational Research, 2003, 141, 179-189.	2.3	18
112	Effects of 3-deazaadenosine on homocysteine and atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis, 2003, 171, 181-192.	0.8	18
113	Expression of the High-affinity Choline Transporter CHT1 in Rat and Human Arteries. Journal of Histochemistry and Cytochemistry, 2003, 51, 1645-1654.	2.5	41
114	Mechanosensitive p27 Kip1 Regulation and Cell Cycle Entry in Vascular Smooth Muscle Cells. Circulation, 2003, 108, 616-622.	1.6	75
115	Protective Effect of 3-Deazaadenosine in a Rat Model of Lipopolysaccharide-Induced Myocardial Dysfunction. Shock, 2003, 19, 245-251.	2.1	11
116	Essential role of complex II of the respiratory chain in hypoxia-induced ROS generation in the pulmonary vasculature. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2003, 284, L710-L719.	2.9	148
117	Mitochondrial Complex II is Essential for Hypoxia-induced ROS Generation and Vasoconstriction in the Pulmonary Vasculature. Advances in Experimental Medicine and Biology, 2003, 536, 163-169.	1.6	32
118	Endothelial Healing in Vein Grafts. Circulation, 2002, 105, 1686-1692.	1.6	73
119	Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies. Nature Medicine, 2002, 8, 1249-1256.	30.7	764
120	Cell Cycle Protein Expression in Vascular Smooth Muscle Cells In Vitro and In Vivo Is Regulated Through Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1152-1158.	2.4	128
121	3-Deazaadenosine Prevents Adhesion Molecule Expression and Atherosclerotic Lesion Formation in the Aortas of C57BL/6J Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2673-2679.	2.4	31
122	A Pressure-Mediated Nonviral Method for Efficient Arterial Gene and Oligonucleotide Transfer. Human Gene Therapy, 1999, 10, 2355-2364.	2.7	27
123	Cyclosporine-induced coronary artery constriction—dissociation between thromboxane release and coronary vasospasm. Journal of Heart and Lung Transplantation, 1999, 18, 328-335.	0.6	11
124	A novel role for the cyclin-dependent kinase inhibitor p27Kip1 in angiotensin II–stimulated vascular smooth muscle cell hypertrophy. Journal of Clinical Investigation, 1999, 104, 815-823.	8.2	113
125	Cell Cycle Progression. Circulation, 1998, 98, 82-89.	1.6	313
126	Comparison of In Vitro Cardiovascular Function with In Vivo Echocardiographic Assessment After Long-Term Administration of Cyclosporine to Rats. Journal of Cardiovascular Pharmacology, 1998, 31, 828-832.	1.9	3

#	Article	IF	CITATIONS
127	The expression of angiotensin-I converting enzyme in human atherosclerotic plaques is not related to the deletion/insertion polymorphism but to the risk of restenosis after coronary interventions. Atherosclerosis, 1997, 130, 203-213.	0.8	37
128	Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo. Transplantation Proceedings, 1997, 29, 614-615.	0.6	43